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Abstract
Background: The implementation of population screening and early prevention strategies targeting individuals at
high-risk for type 2 diabetes (T2D) seems to be a public health priority. The current work aimed to describe the
screening procedure applied in the Feel4Diabetes-study and examine its effectiveness in identifying individuals and
families at high risk, primarily for T2D and secondarily for hypertension, among vulnerable populations in low to
middle-income countries (LMICs) and high-income countries (HICs) across Europe.
Methods: A two-stage screening procedure, using primary schools as the entry-point to the community, was
applied in low socioeconomic status (SES) regions in LMICs (Bulgaria-Hungary), HICs (Belgium-Finland) and HICs
under austerity measures (Greece-Spain). During the first-stage screening via the school-setting, a total of 20,501
parents (mothers and/or fathers) of schoolchildren from 11,396 families completed the Finnish Diabetes Risk Score
(FINDRISC) questionnaire, while their children underwent anthropometric measurements in the school setting.
Parents from the identified “high-risk families” (n = 4484) were invited to participate in the second-stage screening,
including the measurement of fasting plasma glucose (FPG) and blood pressure (BP). In total, 3153 parents participated
in the second-stage screening (mean age 41.1 ± 5.6 years, 65.8% females).
Results: Among parents who attended the second-stage screening, the prevalence of prediabetes (as defined by
impaired fasting glucose; FPG 100-125mg/dl) and T2D (FPG > 126mg/dl) was 23.2 and 3.0% respectively, and it was
found to be higher in the higher FINDRISC categories. The percentage of undiagnosed T2D among the participants
identified with T2D was 53.5%. The prevalence of high normal BP (systolic BP 130-139mmHg and/ or diastolic BP 85-
89mmHg) and hypertension (systolic BP≥ 140mmHg and/ or diastolic BP≥ 90mmHg) was 14 and 18.6% respectively,
which was also higher in the higher FINDRISC categories. The percentage of cases not receiving antihypertensive
treatment among the participants identified with hypertension was 80.3%.
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Conclusion: The findings of the current study indicate that the two-stage school and community-based screening
procedure followed, effectively identified high-risk individuals and families in vulnerable populations across Europe. This
approach could be potentially scalable and sustainable and support initiatives for the early prevention of T2D and
hypertension.
Trial registration: The Feel4Diabetes-intervention is registered at https://clinicaltrials.gov/ (NCT02393872; date of trial
registration: March 20, 2015).
Keywords: Screening, School-based, Vulnerable groups, Type 2 diabetes, Hypertension
Background
Diabetes affects around 8.8% of the adult population world-
wide, and the total number of cases is predicted to rise from
425 million in 2017 to 629 million in 2045 [1]. T2D accounts
for about 90% of all cases of diabetes and it is an important
cause of mortality and morbidity, with its complications im-
posing a great burden both on individuals and healthcare
systems [1, 2]. Furthermore, there is an elevated risk of devel-
oping T2D in vulnerable populations with disadvantaged so-
cioeconomic background, probably due to the higher
prevalence of unhealthy lifestyles in deprived communities
and the barriers to access health care [3–5]. Based on evi-
dence from several clinical trials, T2D is preventable through
lifestyle intervention provided to individuals at increased risk
[6, 7], while early detection of T2D may prevent mortality
and complications [8, 9]. Thus, the implementation of
screening strategies for the identification of high-risk individ-
uals, coupled with non-pharmacological interventions be-
comes a public health priority.
The modifiable risk factors related to T2D (e.g. over-
weight/ obesity, physical inactivity, unhealthy dietary habits)
that are developed in childhood and track into adulthood
[10, 11], potentially increase the future T2D risk. Further-
more, these risk factors tend to cluster within a family, as its
members share common genetic background, but also life-
style, social and physical environment. In this context, inter-
ventions targeting families could be potentially more effective
since the whole family becomes more supportive in adopting
the desired behavior changes [12, 13]. Therefore, trying to
identify families at high risk for developing T2D and invite
them to take part in prevention programs could be a promis-
ing and potentially cost-effective approach, since at least two
generations (i.e. parents and children) can be targeted
simultaneously.
Using a two-stage screening procedure to identify individ-
uals having or being at high risk of developing T2D is an easy
to apply and cost-effective approach [14]. Furthermore, this
approach seems to have an increased response rate com-
pared to other multi-stage screening strategies [15] and is
proposed by the guidelines of several international health or-
ganizations [16, 17]. During the first stage, a non-invasive as-
sessment of risk with a self-reported diabetes risk evaluation
tool is applied. Such a tool is the FINDRISC [18], which is
the most widely used tool in Europe for estimating the future
T2D risk. In the second stage, a diagnostic test (fasting glu-
cose, oral glucose tolerance test [OGTT] or glycated
hemoglobin [HbA1c]) is performed, but only among those
individuals categorized as high-risk in the previous stage.
Although the two-stage screening has been used be-
fore in previous studies, in the vast majority of them its
implementation was opportunistic, including individuals
visiting healthcare services or applying door-to-door
procedures [15]. However, this approach seems to be
less effective in reaching and screening less health-
conscious individuals, early middle-aged adults and vul-
nerable population groups, such as low SES groups [19].
Therefore if we want to reach such populations, an alter-
native systematic, low-cost and potentially sustainable
approach needs to be considered. School setting could
facilitate this need and serve as the entry-point to the
community, in order to identify “high-risk families”.
Considering the above, the Feel4Diabetes consortium,
developed and implemented for the first time a two-
stage screening procedure targeting vulnerable families
in six European countries. Primary schools were used as
the entry-point to the community, aiming to reach and
screen the targeted population (children and their fam-
ilies). The primary aim of the current work was to de-
scribe the procedure of the Feel4Diabetes-screening and
present the relevant results in terms of identifying indi-
viduals and families at high risk for T2D. Furthermore,
since T2D and hypertension share common comorbidi-
ties and risk factors [20], the secondary aim of the
current work was to examine whether the screening
procedure followed could identify also individuals and
families at high risk for hypertension.
Methods
Study background
The current work used the baseline data of the EU-
funded Feel4Diabetes-study (http://feel4diabetes-study.
eu/), which aimed to develop, implement and evaluate a
school- and community-based intervention to prevent
T2D among families from vulnerable groups across
Europe. A detailed description of the study design has
been previously published [21]. Recruitment started in
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January 2016 and measurements were conducted be-
tween April and June in Belgium, Greece and Spain,
while for Finland, Hungary and Bulgaria measure-
ments were extended to September 2016. The
Feel4Diabetes-study was registered at clinicaltrials.gov
as NCT02393872.
Recruitment
Recruitment was based on a standardized, multi-stage
sampling procedure and was conducted within selected
provinces in six European countries. The participating
countries are categorized in three socioeconomic levels
according to the World Bank country classification
based on Gross National Income (GNI) per capita [22]
and the Eurostat’s Government Budget Deficit data in
2014 [23]. Specifically the participating countries were
grouped as follows: LMICs (i.e. Bulgaria and Hungary),
HICs (i.e. Belgium and Finland) and HICs under auster-
ity measures (i.e. Greece and Spain). Since the preva-
lence of T2D tends to be higher in LMICs [24], any
municipality, school district or other equivalent unit in
Bulgaria and Hungary was considered as “vulnerable”
area and eligible to participate in the study. Regarding
HICs, as low SES has been associated with increased risk
of T2D in these countries [3], only low SES regions were
considered as “vulnerable” in Belgium, Finland, Greece
and Spain. Specifically, in these countries low SES re-
gions were defined using the following steps: (i) the mu-
nicipalities, school districts or other equivalent units in
the selected provinces were grouped in tertiles according
to SES indices (i.e. literacy or unemployment rates) re-
trieved from official resources and relevant authorities
[25–28] and (ii) “vulnerable” areas were randomly
selected only from the tertile with the lowest SES
indices.
In each country, primary schools located in the
selected “vulnerable” areas were used as the entry-point
to the community. Children attending the first three
grades of compulsory education as well as their parents
and grandparents (wherever feasible) were recruited to
the study. Of these recruited families, the “high-risk fam-
ilies” were identified based on T2D risk estimation, using
the FINDRISC questionnaire. A family was regarded as
“high-risk” if at least one parent fulfilled the country-
specific cut-off point for FINDRISC that indicated in-
creased T2D risk (for the majority of countries, consid-
ering the young age of the participants, that was set as a
FINDRISC score ≥ 9).
First-stage screening
In the participating schools, teachers distributed the
standardized study questionnaire to all children in the
class to be delivered to their parents/ caregivers [29].
Families were requested to return the completed
questionnaires in sealed envelopes, and the children
from the participating families underwent anthropomet-
ric measurements at school, conducted by trained re-
search assistants [30].
Measurements conducted during the first-stage screening
Questionnaires
Data regarding children’s and parents’ eating, physical
activity and sedentary behaviors, and parents’ sociode-
mographic data were collected, while both parents were
requested to complete the FINDRISC questionnaire. The
most recent version of it consists of eight scored ques-
tions that cover the well-known risk factors of T2D, i.e.
age, body mass index (BMI), waist circumference (WC),
daily physical activity, daily consumption of vegetables
and fruits/ berries, use of antihypertensive medication,
individual’s history of high blood glucose, and family his-
tory of diabetes [31]. The total score indicates the indi-
vidual’s 10-year risk of developing T2D and ranges from
0 to 26, as follows: < 7 (low), 7–11 (slightly elevated),
12–14 (moderate), 15–20 (high) and > 20 (very high). In
order to facilitate the assessment of WC, a paper waist
measuring tape was provided to each family.
Anthropometry
Body weight was measured to the nearest 0.1 kg and
children were weighed in light clothing and without
shoes. Height was measured to the nearest 0.1 cm with
the children standing barefoot, keeping shoulders in a
relaxed position, arms hanging freely and head in Frank-
furt horizontal plane. Two readings were obtained out of
each measurement and the mean was used for the ana-
lysis. A third measurement was conducted if the previ-
ous measurements differ > 100 g for weight and > 1 cm
for height. Weight and height were used to calculate
BMI using Quetelet’s equation [weight (kg)/height (m)2].
The International Obesity Task Force (IOTF) cutoff
points [32] were used to categorize children as “under-
weight”, “normal weight”, “overweight”, or “obese”.
Second-stage screening
Following the first-stage screening and after calculating
the FINDRISC scores and identifying the “high-risk fam-
ilies”, researchers contacted these families in a discrete
manner (to avoid stigmatization of children/ families)
and invited them to attend the second-stage screening,
which was conducted outside the school setting. Specif-
ically, all parents and grandparents (wherever feasible) of
the identified “high-risk families” were invited to
undergo a brief medical check-up delivered in local
community centers or during home visits (in certain
cases in Belgium). In all countries, measurements were
conducted by trained research assistants [30], using stan-
dardized protocols and calibrated equipment. The
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current work focuses on the early identification of T2D
and hypertension among parents (early middle-aged
adults) and therefore grandparents’ data were excluded
from the statistical analysis and relevant tables.
Measurements conducted during the second-stage
screening
Blood indices
Blood samples were drawn in the morning after over-
night fasting for at least 8 h. Participants (parents and
grandparents where feasible) were contacted via phone
calls on the previous day to ensure compliance with fast-
ing. Moreover, they were advised to refrain from taking
their medications in the morning when the blood collec-
tion was performed. Fasting plasma glucose (FPG) was
analyzed in accredited laboratories, using similar enzym-
atic assays in all study centers. Participants were classi-
fied according to the American Diabetes Association
(ADA) criteria [33] in the following categories: normal
(FPG < 100mg/dl; 5.6 mmol/l), prediabetes (FPG 100-
125 mg/dl; 5.6–6.9 mmol/l) and T2D (FPG ≥ 126mg/dl;
7.0 mmol/l).
Blood pressure measurement
Blood pressure (BP) was measured on the right arm, in a
sitting position using an Omron digital blood pressure
measuring device (OMRON M6 or M6 AC) after 5 min
of rest, on three occasions, allowing 1 min interval
among the occasions. Participants were asked to avoid
vigorous exercise, smoking, eating or drinking for 1 h
before the BP measurement. Means of the second and
third measurements were used in the current statistical
analysis. Participants were classified according to the
European guidelines [34] in the following categories: op-
timal or normal (systolic BP < 130 mmHg and/ or dia-
stolic BP < 85mmHg), high normal (systolic BP 130-139
mmHg and/ or diastolic BP 85-89 mmHg) and hyperten-
sion (systolic BP ≥ 140 mmHg and/ or diastolic BP ≥ 90
mmHg), with the BP category to be defined by the high-
est level of BP, either systolic or diastolic.
Anthropometry
Body weight and height were measured in light clothing
and without shoes to the nearest 0.1 kg and 0.1 cm re-
spectively, and WC was measured midway between the
lowest rib margin and the iliac crest to the nearest 0.1
cm. Portable equipment was used [for weight: digital
scales (SECA 813 or 877), for height: telescopic stadi-
ometers (SECA 213 or 214 or 217 or 225), for WC: non-
elastic tapes (SECA 201)]. Two readings were obtained
out of each measurement and the mean was used for the
analysis. A third measurement was conducted if the pre-
vious measurements differ > 100 g for weight, > 1 cm for
height and > 1 cm for WC. BMI and WC were classified
based on the World Health Organization (WHO) criteria
[35].
Questionnaires
Besides data related to lifestyle factors, sociodemo-
graphic data (e.g. age, gender, education, occupation)
and information regarding medical history and medica-
tion use were collected from participants (parents and
grandparents where feasible). Specifically, previous dia-
betes diagnosis was assessed by the question “Has a
physician ever told you that you have diabetes?”, while
medication-treated hypertension was assessed by the
question “Do you currently use drugs for high BP pre-
scribed by a physician?” (Possible answers: yes, no).
Statistical analysis
In the current work the participating countries were
grouped in regions as: HICs (Belgium and Finland),
HICs under austerity measures (Greece and Spain) and
LMICs (Bulgaria and Hungary). A descriptive statistical
analysis was performed by using the Statistical Package
for Social Sciences (SPSS Inc., Chicago, IL, USA), ver-
sion 21.0. Continuous variables are presented as means
± standard deviations and categorical values as propor-
tions (%). Differences in continuous variables were
assessed by parametric (One-Way Analysis of Variance)
or nonparametric tests (Kruskall-Wallis), according to
the distribution of the variables (Kolmogorov-Smirnoff
test), while Pearson’s Chi-square test was used to evalu-
ate the differences in proportions. All statistical tests
were two-tailed and the level of statistical significance
was set at P < 0.05.
Results
The population reached in the Feel4Diabetes-study is
presented in Table 1. Overall, 28,075 families were con-
tacted via the participating 219 primary schools. During
the first-stage screening that was delivered via the school
setting with the completion of a self-reported screening
tool (i.e. FINDRISC), 11,396 families were screened for
T2D risk. All parents and/or grandparents of those fam-
ilies identified with increased risk were invited to the
second-stage screening (a more detailed medical exam-
ination) and finally at least one adult from 2537 “high-
risk families” was measured at baseline, with data avail-
able for 3153 parents.
The descriptive characteristics of the parents and chil-
dren of the “high-risk families” that participated in the
second-stage screening, stratified by region are presented
in Table 2. Parents were aged 41.1 ± 5.6 years and 65.8%
were females. Overall, 65.8% of parents were full-time
employed; while 23.6% of them had less than 12 years of
education, with the latter being lower in HICs. The
prevalence of overweight and obesity was 35.3 and
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36.7%, respectively, in the total sample and it was found
to be lower in LMICs compared to other regions. Finally,
among the participating “high-risk families”, 2711 chil-
dren (aged 8.16 ± 1.0 years; 51.1% girls) were measured.
The prevalence of prediabetes and T2D among the
parents that participated in the second-stage screening is
presented in Table 3. According to the measured FPG
and the ADA criteria, the overall prevalence of prediabe-
tes was 23.2%, while for T2D it was 3.0%. A marked
higher prevalence of prediabetes and T2D was observed
in parents with higher FINDRISC (P < 0.001) in all coun-
tries, as well as in each region (Fig. 1). Overall, among
those parents identified with T2D, 53.5% of participants
were previously undetected, with this percentage being
Table 1 Population reached and screened in the “Feel4Diabetes-study”
Number of All
countries
HICs under
austerity measures
LMICs HICs
Greece Spain Bulgaria Hungary Belgium Finland
Participating schools 219 56 41 20 14 58 30
Families contacted via participating schools 28,075 5195 4823 6541 2902 5367 3247
Families participated in the “first-stage screening” 11,396 2096 1567 2948 1762 1684 1339
Parents provided completed FINDRISC questionnaires (“first-stage screening”) 20,501 3741 3043 5211 3034 2990 2482
Children measured at school setting (anthropometric indices obtained) 12,194 2286 1703 3034 1867 1798 1506
Families identified as “high risk families” and invited to participate in the
“second-stage screening”
4484 907 715 1088 689 475 610
Families participated in the “second-stage screening” 2537 452 541 463 286 420 375
Parents participated in the “second-stage screening” 3153 696 659 554 319 499 426
Grandparents participated in the “second-stage screening” 121 69 –
46
1 5 –
FINDRISC Finnish Diabetes Risk Score, HICs High-income countries, LMICs Low to middle-income countries
Table 2 Descriptive characteristics of parents and children of families participated in the second-stage screening by region
Total sample HICs under austerity measures LMICs HICs P-value*
Parents (n = 2849) (n = 1385) (n = 624) (n = 840)
Age (years) 41.1 (5.56) 42.4 (5.32)a,b 39.6 (5.40)a 40.1 (5.60)b < 0.001
Females, n (%) 1875 (65.8) 837 (60.4)a,b 464 (74.4)a 574 (68.3)b < 0.001
Occupation, n (%)
Work full- time 1875 (65.8) 885 (63.9)a 445 (71.3)a,b 545 (64.8)b < 0.001
Work part- time 335 (11.7) 154 (11.1)a,b 41 (6.5)b,c 140 (16.7)a,c
Stay at home parent 345 (12.1) 203 (14.7)a 83 (13.3)b 59 (7.0)a,b
Unemployed 139 (4.9) 112 (8.1)a,b 8 (1.3)a 19 (2.3)b
Full-time education 31 (1.1) 4 (0.3)a,b 8 (1.3)a 19 (2.3)b
Other** 124 (4.4) 27 (1.9)a,b 39 (6.3)a 58 (6.9)b
Educational level, n (%)
< 12 years 673 (23.6) 373 (26.9)a 160 (25.6)b 140 (16.7)a,b < 0.001
≥ 12 years 2176 (76.4) 1012 (73.1)a 464 (74.4)b 700 (83.3)a,b
Weight status, n (%)
Overweight 1006 (35.3) 506 (36.5)a 185 (29.6)a,b 315 (37.5)b < 0.001
Obese 1045 (36.7) 550 (39.7)a 203 (32.6)a 292 (34.8)
Children (n = 2711) (n = 1089) (n = 753) (n = 869)
Age (years) 8.16 (1.02) 7.80 (0.93)a,b 8.43 (1.00)a 8.36 (1.00)b < 0.001
Females, n (%) 1385 (51.1) 549 (50.4) 393 (52.2) 443 (51.0) 0.752
Data are means (SD) except where noted otherwise
*P-values indicate the significance of the differences among regions
Figures sharing the same superscript letters differentiate significantly from each other
**Other includes “retired” and “something else”
HICs High-income countries, LMICs Low to middle-income countries
Manios et al. BMC Endocrine Disorders 2020, 20(Suppl 1):12 Page 5 of 11
lower in the highest FINDRISC category compared to
the lowest one (P = 0.007).
The prevalence of high normal BP and hypertension
among parents that participated in the second-stage
screening are presented in Table 4. The overall preva-
lence of high normal BP was 14.0%, ranging from 12.7
and 16.7% to 15.7% for participants with FINDRISC
score ≤ 11, 12–14 and ≥ 15, respectively (Fig. 2). The
prevalence of hypertension was 18.6% in the total sam-
ple, while 80.3% of the participants identified with
hypertension were not receiving any antihypertensive
treatment. The prevalence of hypertension was found to
be higher in the higher FINDRISC categories compared
to the lowest one (Fig. 2), while the percentage of partic-
ipants not receiving any antihypertensive treatment
among those identified with hypertension was found to
be lower in the higher FINDRISC categories compared
to the lowest ones (P < 0.001).
The prevalence of overweight or obesity in the chil-
dren of “high-risk families” participating in the second-
stage screening is presented in Table 5. This was found
to be 28.2% in the total sample, with this percentage be-
ing higher if the parents were at higher T2D risk (i.e. at
least one parent with FINDRISC score 12–14 or ≥ 15 vs.
both parents with FINDRISC score ≤ 11, P < 0.001). The
same trend was also observed for HICs under austerity
measures, while no significant differences were found
among parental FINDRISC categories for the other
regions.
Discussion
In the Feel4Diabetes-study, a large number of families
were screened and a relatively high number of parents
were identified to be at high risk for T2D and hyperten-
sion via a two-stage screening procedure, trying to keep
the cost as low as possible. That was realized via the use
of available community infrastructure (primary schools
and local municipality centers) and personnel (i.e.
teachers and healthcare professionals wherever feasible).
The current approach, using the school-setting as the
entry-point to the community, can be a potentially cost-
effective and sustainable community-based approach for
the early identification of high-risk individuals and fam-
ilies for T2D and hypertension and support relevant pre-
vention initiatives. Overall, the implemented screening
procedure as well as the definition and prioritization of
vulnerable population-groups, could guide other similar
strategies both in LMICs and HICs across Europe.
Considering the relatively young age (41.1 ± 5.6
years) of the study population (i.e. parents of
primary-school children), recruited in countries across
Europe, the fact that about only 66% of them re-
ported to be working full-time and almost 25% had
less than 12 years of education, indicate that the aim
of the Feel4Diabetes-study to target primarily vulner-
able groups was achieved to a large extent. Selecting
the most appropriate screening strategy to reach such
a population (i.e. early middle-aged adults and popu-
lations in low SES areas) poses challenges for health-
care professionals. Although opportunistic screening
for T2D among asymptomatic individuals has been
recommended as the most efficient approach [36],
this may lead to selection bias due to reaching the
most motivated individuals. On the other hand, the
door-to-door screening approach can target a large
segment of the population, but it has been reported
to have lower adherence to the diagnostic tests com-
pared to opportunistic screening [37] and may not be
a sustainable and easily scalable approach. To over-
come these issues, the findings of the current study
indicate that applying a two-stage screening using pri-
mary schools as the entry-point to the community
can efficiently reach high-risk families/ individuals.
Therefore, by embedding this procedure into the local
or national school and local healthcare systems, a sys-
tematic, continuous and organized screening could be
Table 3 Prevalence of prediabetes and diabetes in parents participated in the second-stage screening
I II III IVParticipants as presented in
column III, stratified by
FINDRISC category
P-
value*Participants
identified with
prediabetes, n (%)
Participants
identified with
diabetes, n (%)
Participants for whom diabetes
was previously undetected among
those identified with diabetes
in column II, n (%)**
0–11 12–14 15–26
All countries (n = 2685) 623 (23.2) 81 (3.0) 40 (53.5) 13 (81.3)a 13 (64.7) 14 (36.8)a 0.007
HICs under austerity measures
(n = 1249)
304 (24.3) 36 (2.9) 15 (40.0) 4 (57.1) 5 (66.7) 6 (27.3) 0.127
LMICs (n = 644) 84 (13.1) 26 (4.0) 21 (80.0) 8 (100.0) 7 (85.7) 6 (60.0) 0.098
HICs (n = 792) 235 (29.6) 19 (2.4) 4 (36.4) 1 (100.0) 1 (25.0) 2 (33.3) 0.368
*P-values indicate the significance of the differences among FINDRISC categories
Figures sharing the same superscript letters differentiate significantly from each other
** The numbers provided for this variable in the case of HICs do not include data from Finland (n = 7), since participants with previously diagnosed diabetes were
excluded from the study at this study center
FINDRISC Finnish Diabetes Risk Score, HICs High-income countries, LMICs Low to middle-income countries
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delivered at population level and potentially reach the
largest part of the community.
The screening approach used in the Feel4Diabetes-
study managed to identify 3.0 and 23.2% of individuals
with T2D and prediabetes, respectively, and these per-
centages were found to be increased in the higher
FINDRISC categories. These figures seem to be lower
compared to findings from some other studies [38, 39],
possibly due to the screening approach used in the
current study (i.e. targeting the whole population and
not only the health conscious ones or those attending
healthcare services for other health issues), as well as the
Table 4 Prevalence of high normal blood pressure and hypertension in parents participated in the second-stage screening
I II III IVParticipants as presented in column
III, stratified by FINDRISC category
P-
value*Participants
identified
with high
normal blood
pressure, n (%)
Participants
identified with
hypertension, n (%)
Participants not
receiving
antihypertensive
treatment
among those
identified with
hypertension, n (%)
0–11 12–14 15–26
All countries (n = 2723) 382 (14.0) 507 (18.6) 407 (80.3) 231 (89.2)a,b 116 (77.1)a,c 60 (61.7)b,c < 0.001
HICs under austerity measures (n = 1261) 154 (12.2) 156 (12.4) 121 (77.5) 74 (88.8)a 31 (73.2) 16 (53.3)a < 0.001
LMICs (n = 582) 74 (12.7) 119 (20.5) 84 (70.8) 41 (79.6) 29 (68.3) 14 (56.5) 0.121
HICs (n = 880) 154 (17.5) 232 (26.4) 202 (87.0) 117 (93.3)a 55 (85.5) 30 (70.7)a 0.001
*P-values indicate the significance of the differences among FINDRISC categories
Figures sharing the same superscript letters differentiate significantly from each other
FINDRISC Finnish Diabetes Risk Score, HICs High-income countries, LMICs Low to middle-income countries
Fig. 1 Prevalence of prediabetes and diabetes in parents participated in the second-stage screening by FINDRISC category. P-values indicate the
significance of the differences among FINDRISC categories: 0–11 (low and slightly elevated risk), 12–14 (moderate risk), 15–16 (high and very high
risk). Figures sharing the same superscript letters differentiate significantly from each other. FINDRISC: Finnish Diabetes Risk Score; HICs: High-
income countries; LMICs: Low to middle-income countries
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younger age of the participants. Furthermore, 53.5% of
cases identified with T2D were previously undetected.
This is in accordance with current estimations indicating
that almost half of all people with diabetes are undiag-
nosed [1]. It has been also reported that the FINDRISC
questionnaire is considered valid for identifying individ-
uals with undiagnosed T2D and dysglycaemia in the
population under study, while “individuals’ history of
high blood glucose” was the FINDRISC component most
strongly associated with both conditions [40]. In this
context, the proportion of undetected T2D cases was
found to be highest in the lowest FINDRISC category,
probably because these individuals obtained a low score
in the aforementioned FINDRISC component. To some
extent this can be attributed to the fact that many of
these participants may have not previously undergone
Fig. 2 Prevalence of high normal blood pressure and hypertension in parents participated in the second-stage screening by FINDRISC category.
P-values indicate the significance of the differences among FINDRISC categories: 0–11 (low and slightly elevated risk), 12–14 (moderate risk), 15–
16 (high and very high risk). Figures sharing the same superscript letters differentiate significantly from each other. FINDRISC: Finnish Diabetes Risk
Score; HICs: High-income countries; LMICs: Low to middle-income countries
Table 5 Prevalence of overweight or obesity in children of families participated in the second-stage screening
Variables Total
sample
By parental FINDRISC category
Both parents 0–11 At least one parent 12–14 At least one parent 15–26 P-value*
Overweight or obesity in children, n (%)
All countries (n = 2231) 630 (28.2) 267 (24.5)a,b 213 (31.4)a 150 (32.5)b 0.001
HICs under austerity measures (n = 930) 309 (33.2) 126 (28.9)a 100 (35.1) 83 (39.7)a 0.018
LMICs (n = 616) 175 (28.4) 73 (24.6) 64 (32.7) 38 (30.9) 0.119
HICs (n = 685) 146 (21.3) 68 (19.0) 49 (24.9) 29 (22.3) 0.258
*P-values indicate the significance of the differences among parental FINDRISC categories
Figures sharing the same superscript letters differentiate significantly from each other
FINDRISC Finnish Diabetes Risk Score, HICs High-income countries, LMICs Low to middle-income countries
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any glycaemia testing, most likely because of their rela-
tively young age, lack of other risk factors or lack of
awareness [41].
Prevalence of high BP was comparable with other stud-
ies conducted in European countries [42–44], although
with large variations among countries, sexes or SES
groups (relevant data from the Feel4Diabetes-study are
not presented in the current paper). In correspondence
with the prevalence of T2D and prediabetes by FINDRISC
category observed in the current study, a similar trend was
also reported for hypertension and high normal BP, with
the prevalence being higher in the higher FINDRISC cat-
egories. Indeed, data from a prospective study has shown
that FINDRISC can also identify subjects at high risk for
developing hypertension in the long-term [45]. Further-
more, in the Feel4Diabetes-study a high proportion
(≈80.0%) of the individuals identified with hypertension
was not receiving any antihypertensive treatment. Similar
high percentages have been previously reported from
population studies [46]. Based on available literature [46,
47], probably many individuals were not aware of their
condition, but this can only be speculated in the current
study, since the awareness of having hypertension/ high
BP was not assessed. Last but not least, individuals that
had taken medications for high blood pressure on a regu-
lar basis at some point in their life, scored higher in the
FINDRISC. This could probably explain why the propor-
tion of undetected cases of hypertension among the indi-
viduals identified with hypertension was lower in the
highest FINDRISC category.
Finally, about 30% of the children from the families
participating in the second-stage screening were over-
weight or obese, with this percentage being higher in
families that at least one parent was at higher-risk
for T2D based on self-reported FINDRISC data. Overall,
more than 70% of the parents attending the second-
stage screening were found to be overweight or obese.
Given the positive association between parental and chil-
dren’s weight status [48], the implementation of a life-
style intervention targeting the whole family could have
multiple benefits for both high-risk parents and their off-
spring. Emphasizing to parents that serve as role models
for their children [49], could further motivate them to
apply lifestyle changes for their own benefit, as well as
for the benefit of their children.
Conclusions
The findings of the current work demonstrate that the
systematic, two-stage screening procedure implemented
in the Feel4Diabetes-study using the school as the entry-
point to the community can identify individuals and
families at high risk for T2D and /or hypertension. Fur-
thermore, considering the relatively young age of the
adult participants/parents in the current study, a large
proportion of undetected T2D and/or hypertension was
also identified. As the current approach is easy-to-apply
and with relatively low cost, it could be considered
potentially scalable and sustainable for the early identifi-
cation of high-risk individuals and families (also within
vulnerable population-groups), and support initiatives
for the prevention of T2D and hypertension.
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